Companies: 10,795·Total market cap: $144.5T
Interpace Biosciences, Inc.

Interpace Biosciences, Inc.

IDXGOTCHealthcare● Active
$1.68
+$0.01(+0.60%)
Market Cap$46537519
P/E Ratio
52W High$2.4
52W Low$0.697

Interpace Biosciences, Inc. (IDXG) Revenue

Annual & quarterly revenue history · segment & region breakdown

IDXG · revenue · updated Jun 9, 2026

Core revenue metrics

Interpace Biosciences, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
111 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Interpace Biosciences, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
IDXG revenue by year · IDXG revenue history · IDXG annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Interpace Biosciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Interpace Biosciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Interpace Biosciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

IDXG revenue · 4 questions

IDXG's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

IDXG revenueIDXG annual revenuewhat is IDXG revenueIDXG TTM revenue

Source: FMP · Interpace Biosciences, Inc. SEC filings · GAAP · Interpace Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026